Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,439 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Systematic Review with Meta-Analysis: Efficacy and Safety of Lusutrombopag for Severe Thrombocytopenia in Patients with Chronic Liver Disease Undergoing Invasive Procedures.
Orme ME, Bentley R, Marcella S, Peck-Radosavljevic M, Perard R, Wedemeyer H, Yoshiji H, Agarwal K, Dusheiko G. Orme ME, et al. Among authors: agarwal k. Adv Ther. 2022 Sep;39(9):4169-4188. doi: 10.1007/s12325-022-02235-w. Epub 2022 Jul 14. Adv Ther. 2022. PMID: 35836089 Free PMC article.
PROPEL: a randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naïve HCV genotype 1/4 patients.
Wedemeyer H, Jensen D, Herring R Jr, Ferenci P, Ma MM, Zeuzem S, Rodriguez-Torres M, Bzowej N, Pockros P, Vierling J, Ipe D, Munson ML, Chen YC, Najera I, Thommes J; PROPEL Investigators. Wedemeyer H, et al. Hepatology. 2013 Aug;58(2):524-37. doi: 10.1002/hep.26274. Epub 2013 Jun 26. Hepatology. 2013. PMID: 23348636 Clinical Trial.
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.
Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, Shiffman ML, Wedemeyer H, Berg T, Yoshida EM, Forns X, Lovell SS, Da Silva-Tillmann B, Collins CA, Campbell AL, Podsadecki T, Bernstein B. Poordad F, et al. Among authors: agarwal k. N Engl J Med. 2014 May 22;370(21):1973-82. doi: 10.1056/NEJMoa1402869. Epub 2014 Apr 11. N Engl J Med. 2014. PMID: 24725237 Free article. Clinical Trial.
Reply.
Carey I, Cloherty G, Dusheiko G, Agarwal K. Carey I, et al. Among authors: agarwal k. Hepatology. 2021 Feb;73(2):870-871. doi: 10.1002/hep.31468. Hepatology. 2021. PMID: 33118625 No abstract available.
Review article: novel biomarkers in hepatitis B infection.
Lok J, Dusheiko G, Carey I, Agarwal K. Lok J, et al. Among authors: agarwal k. Aliment Pharmacol Ther. 2022 Sep;56(5):760-776. doi: 10.1111/apt.17105. Epub 2022 Jun 30. Aliment Pharmacol Ther. 2022. PMID: 35770458 Review.
Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial.
Yuen MF, Asselah T, Jacobson IM, Brunetto MR, Janssen HLA, Takehara T, Hou JL, Kakuda TN, Lambrecht T, Beumont M, Kalmeijer R, Guinard-Azadian C, Mayer C, Jezorwski J, Verbinnen T, Lenz O, Shukla U, Biermer M; REEF-1 Study Group. Yuen MF, et al. Lancet Gastroenterol Hepatol. 2023 Sep;8(9):790-802. doi: 10.1016/S2468-1253(23)00148-6. Epub 2023 Jul 10. Lancet Gastroenterol Hepatol. 2023. PMID: 37442152 Clinical Trial.
1,439 results